Activity Preview


FOCUS Quiz: Winter 2019 - Neuroscience-Informed Therapies in Psychiatry

Activity Type:

  • Journal CME

Release Date: 1/1/2019

Expiration Date: 12/31/2021

  • AMA PRA Category 1: 5
  • Participation: 5

Access Activity


Neuroscience-Informed Therapies in Psychiatry

FOCUS, APA's clinical review and continuing medical education journal, is designed as a personal study resource to help practicing psychiatrists keep abreast of significant advances in the field, with particular attention to clinical practice and incorporation of core competencies. The goal of FOCUS is the dissemination of up-to-date clinical information, facilitation of lifelong learning skills, maintenance of certification, and opportunity for self-assessment in order to improve patient care. Each issue, prepared by distinguished faculty who are recognized in their fields, provides up to date clinical information and incorporates a CME component. The material can be used effectively by establishing a regular schedule of study.


This activity is only available to 2019 Focus subscribers.

Don't have a subscription to 2019 Focus? Subscribe online or by phone at 1-800-368-5777.  

If you have questions about Focus subscriptions, please contact

Educational Objectives

This issue of FOCUS provides the reader with a review of approaches to neuroscience informed treatments, some of which have been used in psychiatry for some time and are now better understood from the neuroscience perspective.

Participants will

  • better understand the neuroscience perspective and  be able to identify the effects of ketamine on neurotransmitter systems as well as its mechanism of action, concerns of use, and need for treatment guidelines.
  • synthesize information regarding the clinical effects, neurocognitive effects, and possible mechanisms of action of non-invasive neuromodulation therapies used in the treatment of depression including ECT, transcranial magnetic stimulation (TMS), magnetic seizure therapy (MST), and transcranial direct current stimulation (tDCS)
  • be better able to inform their interactions and communication with patients and be inspired to use a clinical neuroscience perspective in practice.

Target Audience

This program is one element of a lifelong learning program for psychiatrists and is an aid for psychiatrists and other clinicians participating in maintenance of certification.

Estimated Time to Complete

Estimated Duration: 5 hours
Begin Date: January 1, 2019
End Date: December 31, 2021

How to Earn Credit

In order to earn CME credit, participants should read through the material presented in the issue. After reading the materials, complete the CME quiz by answering multiple-choice questions with a single correct answer. A score of 60% or higher is required to receive credit. Retakes are available for the test. Review the rationales, complete the online course evaluation, and then claim and print your CME certificate. The APA provides a CME certificate of credit for physicians and a certificate of participation for non-physicians.

Continuing Education Credit

The American Psychiatric Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The APA designates this journal-based CME activity for a maximum of 5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Faculty and Planner Disclosures

Program Planners – Editor, Associate Editors, and Guest Editor

Mark H. Rapaport, M.D., Editor of FOCUS, and Chairman and Chief of Psychiatric Services, Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, Ga. No financial relationships with commercial interests.

Dorothy Stubbe, M.D., Editor and Author, Communications Commentary, Associate Professor and Program Director, Yale University School of Medicine Child Study Center, New Haven, CT.- No financial relationships with commercial interests.

Laura Dunn, M.D., Co-Editor Ethics Column; Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, CA; Dr. Dunn reports: Consultant: Otsuka America Pharmaceutical Inc.

Ian A. Cook, M.D., D.F.A.P.A., Section Editor and Author Patient Management: Dr. Cook is with the Semel Institute for Neuroscience and Human Behavior at the University of California, Los Angeles, and is in practice at the Los Angeles TMS Institute. Dr. Cook reports that his active biomedical device patents are assigned to the University of California. In the last year, he has advised HeartCloud, Inc., and the BrainCloud Corporation, and the University of California, Los Angeles, has received research grant funding from NeoSync, Inc., for his work. He has been granted stock options in NeuroSigma, the licensee of some of his inventions, and he currently is on leave as its chief medical officer and senior vice president. He is director of the Los Angeles TMS Institute, Inc., and chief executive officer at HeartCloud, Inc., and the BrainCloud Corporation, as well as Professor Emeritus at UCLA.

Boadie Dunlop, M.D., Section Editor, Applied Armamentarium, Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, Georgia.  Grant/Research: Axome, Assurex, Acadia, Janssen, NIMH, Takeda

Mayada Akil, M.D., Georgetown University Hospital Department of Psychiatry

Bringing Neuroscience to the Bedside

Joseph Cooper, M.D., University of Illinois at Chicago, Department of Psychiatry

Alexander Korb, M.D., Semel Institute for Neuroscience, UCLA Psychiatry

Mayada Akil, M.D.; Georgetown University Hospital, Department of Psychiatry

Drs. Cooper and Akil have nothing to disclose. Dr. Korb is a consultant for and owns shares in Brainsonix Inc. and receives author royalties from New Harbinger Publications.

Therapeutic Uses of Seizures in Neuropsychiatry

M. Justin Coffey, M.D., Medical Director, Center for Brain Stimulation, The Menninger Clinic Associate Professor of Psychiatry & Behavioral Sciences Baylor College of Medicine

Joseph J. Cooper, M.D., Associate Professor of Clinical Psychiatry University of Illinois at Chicago

Dr. Cooper has nothing to disclose. Dr. Coffey reports authorship royalties from UpToDate 2. Authorship royalties from MedLink Neurology

Ketamine for Treatment-Resistant Mood Disorders

Lawrence T. Park, M.D., Tolulope B. Falodun, BS, and Carlos A. Zarate Jr., M.D., Section on Neurobiology and Treatment of Mood Disorders, National Institute of Mental Health, National Institutes of Health, Bethesda, MD

Dr. Zarate is listed as a co-inventor on a patent for the use of ketamine in major depression and suicidal ideation; as a co-inventor on a patent for the use of (2R,6R)-hydroxynorketamine, (S)-dehydronorketamine, and other stereoisomeric dehydro and hydroxylated metabolites Tolulope of (R,S)-ketamine metabolites in the treatment of depression and neuropathic pain; and as a co-inventor on a patent application for the use of (2R,6R)- hydroxynorketamine and (2S,6S)-hydroxynorketamine in the treatment of depression, anxiety, anhedonia, suicidal ideation, and post-traumatic stress disorders. He has assigned his patent rights to the U.S. government but will share a percentage of any royalties that may be received by the government. All other authors have no conflict of interest to disclose, financial or otherwise.

Transcranial Direct Current Stimulation in Psychiatry: What Psychiatrists Need to Know

Amin Zand Vakili, M.D., Ph.D, Yosef Berlow, M.D., Ph.D., Noah Stephen Philip, M.D., Center for Neurorestoration and Neurotechnology, Providence VA Medical Center, Department of Psychiatry and Human Behavior, Alpert Medical School of Brown University, Providence RI,

Linda Leigh Carpenter, M.D., Alpert Medical School of Brown University, Providence RI, and Butler Hospital, Neuromodulation Research Facility, Providence, RI.

In the last three years, Dr. Philip has received grant support (through clinical trial contracts) from Neuronetics and Neosync. Dr. Carpenter reports: Consultant: Magstim LTD, Feelmore Labs Inc.; Grant/Research: Neuronetics, NeoSync, Janssen. Dr. Berlow and Dr. Zand Vakili report no conflicts.

A Critical Review and Synthesis of Clinical and Neurocognitive Effects of Non-Invasive Neuromodulation Antidepressant Therapies

Shawn M. McClintock, Ph.D., MSCS, Neurocognitive Research Laboratory, Department of Psychiatry, UT, Southwestern Medical Center, Dallas, TX, USA; Division of Brain Stimulation and Neurophysiology, Department of Psychiatry and Behavioral Sciences, Duke University School of Medicine, Durham, NC

Dr. McClintock reports grant support from the National Institutes of Health (NIH), and teaching honoraria from TMS HealthSolutions.

Elisa Kallioniemi, Ph.D., Department of Psychiatry, UT Southwestern Medical Center, Dallas, TX, USA

Dr. Kallioniemi reports no competing interests

Donel M. Martin, Ph.D., Black Dog Institute, Sydney, Australia; School of Psychiatry, University of New South Wales, Sydney, Australia

Dr. Martin reports grant support from the Brain and Behavior Foundation, travel support from Miyuki Giken, and a speaker’s honorarium from Lundbeck.

Joseph U. Kim, Ph.D., Department of Psychiatry, University of Utah School of Medicine, Salt Lake City, Utah, USA

Dr. Kim reports grant support from the National Institutes of Health (NIH).

Sara L. Weisenbach, Ph.D., Department of Psychiatry, University of Utah School of Medicine, Salt Lake City, Utah, USA; VA Salt Lake City, Mental Health Program, Salt Lake City, Utah, USA.

Dr. Weisenbach reports grant support from the National Institutes of Health (NIH) and the Department of Veterans Affairs

Christopher C. Abbott, M.D., M.S., Department of Psychiatry, University of New Mexico School of Medicine.

Dr. Abbott reports grant support from the National Institutes of Health (NIH).

How Neuroscience is Informing Treatments: Ethical Issues

Kristina Thurin, M.D., Zehra N. Aftab, M.D., Joseph J. Cooper, M.D., University of Chicago, Department of Psychiatry and Behavioral Neuroscience. The authors report no financial relationships with commercial interests.

Neuroscience and the Future of Psychiatry

Michael J. Travis, M.D., Associate Professor, Director of Residency Training, Department of Psychiatry, Western Psychiatric Institute and Clinic of UPMC Dr Travis reports no financial relationships with commercial interests

American Psychiatric Association Staff Involved in Planning:  

Tristan Gorrindo, M.D., Director, Division of Education, APA – no conflicts

Kristen Moeller, Director of CME, Associate Director of FOCUS -- no conflicts

Hardware/Software Requirements

This internet-based CME activity is best experienced using Internet Explorer 8+, Mozilla Firefox 3+, Safari 4+. This Web site requires that JavaScript and session cookies be enabled. Certain activities may require additional software to view multimedia, presentation, or printable versions of the content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Adobe Acrobat, Microsoft PowerPoint, and Windows Media Player.

Optimal System Configuration

  • Flash Player: Adobe Flash Player 10.1+ 
  • Browser: Firefox 3+, Internet Explorer 8.0+, Safari 4.0+, or Google Chrome 7.0+ 
  • Operating System: Windows XP+ or Mac OS X 10.4+ 
  • Internet Connection: 1 Mbps or higher

Minimum Requirements

Windows PC:
500-MHz Pentium II; Windows XP or higher; 128 MB RAM; Video Card at least 64MB of video memory; Sound Card at least 16-bit; Macromedia Flash Player 10 or higher, audio playback with speakers for programs with video content; Firefox 1.1+, Internet Explorer 7.0+, Safari 1.0+, Google Chrome, or Opera

Mac OS X 10.3 or higher with latest updates installed; 1.83MHz Intel Core Duo or faster; RAM: 128MB or more; Video Card: at least 64MB of video memory; Sound Card: at least 16-bit

For assistance: Contact for questions about this course | Contact for technical assistance

Access Activity